Last update :
13/11/2024
Stability and compatibility of drugs

Welcome in Stabilis. If you wish to receive the quarterly newsletter, indicate your email address.

Sign up

If you have any questions or comments, please contact : infostab@stabilis.org

Database  
References : 2788
Compounds : 872
Pharmacological Class : 46
Stability of solutions : 6421
Stability in mixtures : 1254
Compatibility : 12576
Trade Name : 5059
News - Compounds  
Various Ointments Hydroquinone 13/11/2024
Various Ointments Enoxolone 13/11/2024
Antibiotic Ointments Dapsone 13/11/2024
Various Ointments Adapalene 13/11/2024
Antibiotic Ointments Clarithromycin 18/10/2024
Various Eye-drops Methylprednisolone sodium succinate 08/07/2024
Various Ointments Dutasteride 12/06/2024
Various Ointments Clobetasol propiomate 12/06/2024
Vitamin Ointments Nicotinamide 12/06/2024
Various Ointments Cafeine 04/06/2024
Anticancer drug injection Pevonedistat 03/06/2024
Antibiotic Oral solution Clofazimine 15/04/2024
Anti-inflammatory Ointments Diclofenac 08/04/2024
Various injection Angiotensin II 02/04/2024
Various injection Ranibizumab 08/03/2024
Various injection Faricimab 08/03/2024
Various injection Disodium glucose-1-phosphate tetrahydrate 18/01/2024
Antiviral injection Remdesivir 13/09/2023
Neuroleptic Oral solution Lurasidone 28/08/2023
Various Capsule Cholic acid 12/06/2023
News - References  
Date of Entry
4857 Physicochemical and Microbiological Stability of Compounded Clonidine Hydrochloride Oral iquid Dosage Forms in PCCA Base, SuspendIt®. Int J Pharm Compound 04/09/2024
4859 Physicochemical and Microbiological Stability of Compounded Bethanechol Chloride Oral Suspensions in PCCA Base, SuspendIt® Int J Pharm Compound 04/09/2024
4862 Erwinase, 10,000 IU/vial, Powder for solution for injection/infusion - Summary of Product Characteristics Updated 04-Jul-2022. Porton Biopharma Limited 04/09/2024
4852 KEYTRUDA 25 mg/mL solution à diluer pour perfusion. Résumé des caractéristiques du produit. Merck Sharp & Dohme B.V. 25/08/2024
4849 Formulation and Stability of a 1% Clarithromycin-Based Topical Skin Cream: A New Option to Treat Buruli Ulcers? Pharmaceuticals 22/08/2024
4846 Chemical Stability of Lorazepam Oral Solution Repackaged in Plastic Oral Syringes at Room and Refrigerated Temperature. Hosp Pharm 03/07/2024
4843 Y-Site Compatibility Studies of Ketoprofen with Parenteral Nutrition Admixtures for Central and Peripheral Administration. Pharmaceutics 30/06/2024
4842 Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors Drug Design Dev Ther 28/06/2024
4837 Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 16/06/2024
4828 The Physical Compatibility of Glycopyrrolate and Rocuronium. Anesth Prog 15/06/2024
4831 Frequently acquired drugs in neonatal intensive care and their physical compatibility. Acta Paediatr 15/06/2024
4832 Co‑administration of drugs with parenteral nutrition in the neonatal intensive care unit—physical compatibility between three components. Eur J Pedia 15/06/2024
4824 Physicochemical stability of pevonedistat at 50, 100 and 200 µg/mL diluted in 0.9% sodium chloride and at 10 mg/mL in partially used vials. EJHP 03/06/2024
4825 Physicochemical and microbiological stability study of two new preservative-free methylprednisolone eye drops. Farm Hosp 03/06/2024
4822 Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. JAC Antimicrob Resist 08/05/2024
4821 AmBisome® Formulations for Pediatrics: Stability, Cytotoxicity, and Cost-Effectiveness Studies. Pharmaceutics 28/04/2024
4820 Physicochemical and biological stability of diluted vedolizumab in intravenous infusion bags. EJHP 17/04/2024
4819 Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations. Int J Pharm 09/04/2024
4818 Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022 PAION UK Ltd 04/04/2024
4816 Stability Evaluation of Bracketed Diclofenac Sodium USP in VersaPro Cream Base, Versa Pro Gel Base and PLO Gel Mediflo30 Compound Kit. Int J Pharm Compound 26/03/2024
4813 Compatibility of Various Hormones in Phytobase and HRT Heavy Cream Bases Int J Pharm Compound 25/03/2024
4814 Compatiblity of Caffeine, Clobetasol Propionate, Dutasteride, Nicotinamide, and Progesterone in TrichoFoam, a Natural Vehicle for Hair Forms. Int J Pharm Compound 25/03/2024
4812 Stability of extemporaneously prepared clofazimine oral suspensions J Pharm Pract and Res 20/03/2024
4808 Characterizing the Stability of Angiotensin II in 0.9% Sodium Chloride Using High Performance Liquid Chromatography and Liquid Chromatography Tandem Mass Spectrometry. Hosp Pharm 06/03/2024
4807 Vectibix 20 mg/mL concentrate for solution for infusion. Summary of Product Characteristics Updated 13-Jul-2023 Amgen Ltd 21/02/2024
4801 Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 18/01/2024
4802 Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit Aguettant Laboratory 18/01/2024
4798 A silicone Oil-Free Syringe Tailored for Intravitreal Injection of Biologics. Frontiers in Ophthalmology 12/01/2024
4799 Stability of Voriconazole 10 mg/mL in IsoptoTears 0.5% stored in Glass Vials And Low Density Polyethylene Droppers at 4°C and 25°C for 28 Days. 12/01/2024
4800 Stability of Dr.Reddy’s Cabazitaxel Following Reconstitution with Manufacturer’s Diluent & Dilution with Sodium Chloride and Dextrose 5% in non-PVC non-DEHP bags and Original Glass Vials at 25°C, 4°C and -20°C. 12/01/2024

  Mentions Légales